StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
BHCBullishEarningsnews
High materiality8/10

Bausch Health lifts 2026 outlook on strong Q3 results and buyback

Oct 28, 2026, 6:00 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong Q3 beat, guidance raise, and a 50M buyback improve earnings visibility and reduce dilution, supporting multiple expansion; tariff uncertainty provides some downside guardrails.

AI summary

What happened, with direct paths to the underlying reporting

Bausch Health posted a solid Q3 2026 with revenue of $2.94B, up 10% YoY, and raised full-year guidance. Adjusted EPS rose 53% to $1.77 and Adjusted EBITDA hit $1.305B, while operating cash flow reached $813M and cash on hand rose to $2.485B. The board authorized a $50M share repurchase to offset 2027 dilution, signaling confidence in cash generation and balance-sheet strength amid tariff uncertainty and potential strategic moves around Bausch + Lomb.

  • Q3 2026 revenue $2.941B, up 10% YoY. Organic growth 8%.
  • Adjusted EPS $1.77; GAAP EPS $1.15. Net income up strongly.
  • Adjusted EBITDA $1.305B, up 32%. Excluding B+L, EBITDA exceeded $1B.
  • Board approves $50M share repurchase to offset 2027 dilution.
  • Guidance raised for 2026 revenue and Adjusted EBITDA.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event